Abstract
Background Over 10 years after the establishment of the National Health Insurance Scheme (NHIS) in Ghana, the use of a median pricing methodology for pharmaceuticals remains a topic of debate due to its positive and negative outcomes. Residual effects of this pricing methodology include proliferation of low-quality medicines, irrational medicine use, insurance fraud and other untoward outcomes. Of particular interest is the ripple effect of this median pricing policy on the entire pharmaceutical system. Ghana’s pharmaceutical system has limited local production capacity and is heavily dependent on importation. Medicine prices continue to rise and the medicine reimbursement value constitutes an increasingly larger proportion of overall claims values. With finite resources allocated to the NHIS, this presents a sustainability challenge to be addressed promptly.
Highlights
Over 10 years after the establishment of the National Health Insurance Scheme (NHIS) in Ghana, the use of a median pricing methodology for pharmaceuticals remains a topic of debate due to its positive and negative outcomes
Influential factors including importation fees, foreign exchange, demand and supply chain challenges are not considered in the median pricing methodology
Anecdotal and quantitative evidence indicates the critical need for a revised pricing policy to include the key pricing factors in the near future
Summary
Over 10 years after the establishment of the National Health Insurance Scheme (NHIS) in Ghana, the use of a median pricing methodology for pharmaceuticals remains a topic of debate due to its positive and negative outcomes. The impact of Ghana’s National Health Insurance Scheme median pharmaceutical pricing methodology and reimbursement policy on the pharmaceutical system From 3rd International PPRI Conference 2015: Pharmaceutical Pricing and Reimbursement Policies: Challenges Beyond the Financial Crisis Vienna, Austria. Background Over 10 years after the establishment of the National Health Insurance Scheme (NHIS) in Ghana, the use of a median pricing methodology for pharmaceuticals remains a topic of debate due to its positive and negative outcomes.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
